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KESAN ETANERCEPT DAN NANOPARTIKEL EMAS KE ATAS 
EKSPRESI SEL T PENGAWALSELIA TNFR2+ DAN SEL DENDRITIK 
CD103+ DI DALAM SEL MONONUKLEAR DARAH PERIFERAL PESAKIT 
ASMA 
 ABSTRAK 
Toleransi imun oleh sel T pengawalselia (Tregs) adalah salah satu daripada 
pelbagai mekanisma yang digunakan untuk mengekalkan homeostasis dan 
melindungi perumah terhadap pelbagai rangsangan alam sekitar. Belakangan ini, 
sebahagian daripada Tregs yang mempunyai pengekspresian TNFR2 (TNFR2+ 
Tregs) dikenalpasti sebagai populasi sel yang lebih menekan dan proliferatif; 
manakala pengawalaturannya dilaporkan terganggu dalam masalah pernafasan 
seperti asma. Nanopartikel emas (AuNPs), yang sangat berpotensi dalam terapi 
imun, telah dilaporkan melindungi manusia daripada ciri-ciri utama asma. Oleh itu, 
kajian ini ingin merungkai kesan AuNPs terhadap pengekspresian TNFR2+ Tregs, 
dan juga pada CD103+ sel dendritik (DCs), yang telah ditunjukkan mendorong Tregs 
dalam pesakit asma. Kajian ini juga ingin mengkaji kesan AuNPs terhadap populasi 
sel kajian dengan TNF yang juga dilaporkan penting dalam perkembangan asma 
menggunakan etanercept, salah satu anti-TNF. Kaedah flow cytometry lima warna 
digunakan untuk menentukan pengekspresian populasi sel kajian dalam pesakit asma 
dan individu bukan asma (n = 6) dan ujian ELISA digunakan untuk menentukan 
tahap TNF-α dan IL-10. Stimulasi sel mononuklear darah periferal (PBMCs) pesakit 
asma dengan AuNPs selama 24 jam memperlihatkan AuNPs tidak memberi kesan 
signifikan kepada populasi sel kajian. Manakala, sebagai anti-TNF, etanercept dilihat 
 
mengurangkan secara signifikan TNFR2+ Tregs (p = 0.0210) dan sel T efektor 
TNFR2+ (Teff) (p = < 0.0001) namun memperlihatkan kadar peningkatan untuk 
Tregs sahaja. Yang mengejutkan, etanercept ditunjukkan dengan ketara 
meningkatkan tahap TNF-α, mempersoalkan mekanisma utama etanercept sebagai 
antagonis TNF. Dalam analisis korelasi, populasi Tregs termasuklah TNFR2+ Tregs  
dikawal selia secara songsang oleh CD103+ DCs (r = - 0.6853, p = 0.0170), 
menunjukkan subset DCs ini tidak terlibat dalam regulasi homeostasis imun, 
terutamanya dalam keadaan asma. Secara keseluruhan, keputusan kajian 
menunjukkan AuNPs boleh digunakan sebagai pembawa formulasi berpotensi untuk 
terapi imun kerana kemampuannya untuk dikenalpasti oleh sel penyaji antigen 











EFFECT OF ETANERCEPT AND GOLD NANOPARTICLES ON THE 
EXPRESSION OF TNFR2+ REGULATORY T CELLS AND CD103+ 
DENDRITIC CELLS IN PERIPHERAL BLOOD MONONUCLEAR CELLS 
OF ASTHMA PATIENTS 
 ABSTRACT 
Immune tolerance by regulatory T cells (Tregs) is one of the various 
mechanisms, which is employ to maintain homeostasis and protect the host against 
various environmental stimuli. Recently, a subset of Tregs expressing tumor necrosis 
factor receptor 2 (TNFR2+ Tregs) is identified as a more suppressive and 
proliferative cell population and its regulation is reported to be impaired in 
respiratory dysfunction condition such as asthma. Gold nanoparticles (AuNPs), a 
highly potential tool in immunotherapies, are shown to be protective against key 
features of asthma. Hence, the current study would like to elucidate the effects of 
AuNPs on the expression of TNFR2+ Tregs, as well as on CD103+ dendritic cells 
(DCs), which have been shown to induce Tregs in asthmatic individuals and whether 
a TNFR2 agonist, etanercept, can modulate the effects of AuNPs. A five-color flow 
cytometry assay was used to determine the expression of cell population of interest 
in asthmatic and non-asthmatic controls (n=6) and traditional ELISA assay to 
determine the level of TNF-α and IL-10. Stimulation of peripheral blood 
mononuclear cells (PBMCs) of asthmatic individuals with AuNPs for 24 hours does 
not induce significant effects on the cell population of interest. Meanwhile, 
etanercept as anti-TNF is shown to significantly decrease TNFR2+ Tregs (p = 
0.0210) and T effector cells TNFR2+ (Teff) (p = < 0.0001) with an increased pattern 
 
of Foxp3+ Tregs only. Surprisingly, etanercept is shown to significantly increased the 
level of TNF-α, question the principal mechanism of etanercept as TNF antagonist. 
Correlation analysis in the current study demonstrated inverse association of CD103+ 
DCs with Tregs including TNFR2+ Tregs (r = - 0.6853, p = 0.0170), indicates to the 
independency of this subset of DCs in the regulation of immune homeostasis, 
particularly in asthma. Results indicated to the potential of AuNPs as potential 
formulation carrier for immunotherapies due to its capability to be effectively uptake 
by antigen-presenting cells such as DCs without inducing immune response. 
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CHAPTER 1  
          INTRODUCTION 
1.1 Background of research 
The lung is constantly exposed to a diverse stimuli including air pollution particulates 
and microbial products which resulted in an immune activation or suppression 
depending on the nature of stimuli (e.g. doses, characteristics), exposure route/time 
and the lung microenvironment (e.g. host immune system). Thus, the lung must 
maintain a state of immune tolerance to these stimuli to retain pulmonary homeostasis 
and prevent immunopathology such as asthma. Asthma is a chronic obstructive 
pulmonary disease that implicated nearly 300 million people worldwide. The 
immunobiology of asthma is when both the innate and the adaptive immune responses 
act together to cause the bronchial hyperresponsiveness, airway narrowing and 
remodelling as well as mucus overproduction. One of the mechanisms to maintain 
immune homoestasis in the lung is through the induction of tolerance. Regulatory T 
cells (Tregs) have been established as the key player in the maintenance of tolerance 
and in asthma the phenotype and function of this subset of cell is severely 
dysregulated. Tregs expressing TNFR2 (CD25+FoxP3+TNFR2+ Tregs) have been 
shown to have a more potent immune regulatory function than the TNFR2-negative 
Tregs and have a higher capacity to expand in vivo. This subset of Tregs is strictly 
regulated by membrane-bound TNF, which is preferentially expressed on Tregs, lead 
to increase proliferation. Other than Tregs, CD103+ dendritic cells (DCs), which 
constituted as the major DCs in the lung, is shown to promote tolerance although 
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some contrasting observations are available as well. Hence, induction of these two 
cells population to promote tolerance serves as a new potential in asthma therapy. 
Current study aims to investigate the phenotype of TNFR2 expressing Tregs and 
CD103+ DCs in asthma patients and their responses in the presence of external 
stimuli, for instance nanoparticles. Nanoparticles such as gold is demonstrated to 
possess desirable characteristics including versatile surface functionalization, 
customizable size and shape and low cytotoxicity, select them as potential tool to 
target cell population of interest.  
1.2 Statement of problem 
Pathogenesis of asthma is associated with the dysregulation of immune homeostasis in 
the airways in terms of augmentation of inflammation and reduction of tolerance. 
Although the intervention of asthma managed to control the symptoms, however it 
does not modify the course of the disease and continues to impose great burden in 
terms of productivity and medical costs and even morbidity. Immune-modifying 
therapies such as allergen-specific immunotherapy (SIT) have been proposed as a 
potential in asthma therapy and the success of nanoparticles such as AuNPs, as a tool 
in immunotherapy, excites the idea. AuNPs have been well established to possess 
advantageous properties to be a highly potential tool in immunotherapy. This study 
aims to investigate the effect of AuNPs on the regulation of TNFR2 expressing Tregs 
and CD103+ DCs and whether the presence of TNF antagonist such as etanercept 
would modulate the effect of AuNPs. It has been shown that TNF is responsible to the 
inflammatory cascades in asthma through the increased of TNF levels in asthma 
patients. This study will not only contribute significantly to the understanding of these 
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two cell populations that might play an important role at the homeostatic level and 
during airway inflammation in healthy and asthmatic individuals respectively, but also 
to the modulation of these cells upon exposure to nanoparticles. This might include 
the chances of targeting Foxp3+ Tregs expressing TNFR2 using nanoparticles to be 
translated as a biological therapy to maintain and restore immune homeostasis, as now 
it is being highly investigated in human to selectively expand Tregs into homogenous 
progeny with potent suppressive function. 
1.3 Hypotheses 
This study hypothesized that the expression of TNFR2 on Tregs in PBMC of 
asthmatic and non-asthmatic controls would distinctly be affected by both stimuli, 
AuNPs and etanercept, regulated by DCs including CD103+ DCs (Figure 1.1).  AuNPs 
will be uptake by the APCs such as DCs and induce the release of mediators that 
would affect the expression of cell population of interest. Meanwhile, etanercept 
would neutralize TNF in the system, thus provides an insight on the mechanism of 




Figure 1.1 Framework of the study. TNF produced by immune cells (dendritic cells, effector T cells) in asthma condition bind to TNFR2 that 
expressed on Treg and effector T cells in an autocrine and paracrine manner. AuNPs affect the cellular uptake and phenotype of DCs such as 
CD103+ DCs and both CD4+CD25+TNFR2+ Treg and TNFR2+ effector cells, and the addition of TNF antagonist (e.g. etanercept) differently 
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1.4 Research questions 
The aforementioned hypothesis on the expression of TNFR2 on Tregs and CD103+ 
DCs on PBMC of asthmatic and non-asthmatic individuals of this study are motivated 
for answering the following research questions: 
a. Do external stimuli such as AuNPs play a role in the secretion 
of TNF in PBMC of asthmatic and to what extent this would 
affect cell population of interest? 
b. Do neutralization of TNF by anti-TNF such as etanercept would 
differently regulate the effect of AuNPs to PBMC of asthmatic? 
c. What are the associations of these effects with clinical 
characteristics? 
1.5 Objective 
1.5.1 General objective 
To determine the effects of AuNPs and etanercept on the expression of TNFR2 




1.5.2 Specific objectives 
a. To determine the proportion of lymphocytes and DCs subsets in 
PBMCs of asthmatic and non-asthmatic controls 
b. To assess the expression of TNFR2 expressing Tregs and CD103+ 
DCs in asthmatic and non-asthmatic controls after exposure to 
AuNPs and etanercept 
c. To assess the cytokine levels of asthmatic and non-asthmatic controls 
after exposure to AuNPs and etanercept 








1.6 Flowchart of the study 
 
Recruitment of asthma and non-asthmatic individuals 
Assess 10 ml PBMC from 
each subject 
PBMC separation by  
Ficoll gradient 
centrifugation 
Characterization of  
gold nanoparticles 




Culture PBMC with conditions as below: 
Medium only  
Lipopolysaccharides & medium 
AuNPs & medium 
Etanercept & medium 




phenotyping by flow 
cytometry to determine 
the proportions of T cells 
and antigen presenting 
cells 
Flow cytometry analysis for expression of 
T cells and antigen presenting cells  
(CD3, CD4, CD25, TNFR2, Foxp3, 
MHCII, CD11c, CD11b, CD86, CD103) 
Keep cell 
supernatant in 




ELISA  assay 
Correlation study 
24/48 hour, 37°C, 5% CO2 
Ethical approval from Human Research Ethic Committee USM 
Meet study criteria with verbal and written consent 
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CHAPTER 2  
 LITERATURE REVIEW 
2.1 Asthma 
Asthma is a chronic obstructive pulmonary disease characterized by coughing, 
wheezing, shortness of breath and chest tightness, resulting to difficulty in breathing 
(Global Inititative for Asthma, 2019). Since the disease is a very common disease, 
affecting almost 300 million people worldwide and 4.5% of Malaysian population 
(Institute for Public Health, 2008), it imposed a huge burden to the society in term of 
the loss of productivity and huge healthcare expenditure. The symptoms of asthma are 
potrayed as both innate and adaptive immune responses act together to cause 
bronchial hyperreactivity, mucus overproduction, airway wall remodeling and airway 
narrowness. Asthma can be divided into several phenotypes, differing in their clinical 
manifestations, pathophysiology and even demographic location, but mainly asthma is 
categorized into allergic and non-allergic asthma (Wenzel, 2012). Allergic asthma, 
which comprised of nearly 50% of asthma patients, characterized by the presence of 
serum immunoglobulin E (IgE) antibodies and/or positive for common allergen-
specific antibodies. This type of asthma usually develops from allergy sensitization 
occurred in childhood, accompanied by other types of allergy such as eczema and 
allergy rhinitis, with a positive family history of asthma (Bosnjak et al., 2011). 
Meanwhile, non-allergic asthma, also called adult-onset asthma as it develops later in 
life, does not involve any IgE reactivity to allergens and often requires long-term 
treatment with systemic steroids (Barnes, 2009). Asthma manifestations also can be 
 
9 
induced by vigorous physical activities, smoking, viral infection and obesity. Asthma 
is clinically controlled with inhaled or oral corticosteroid mostly in combination with 
short- or long-acting β-agonist that have a broad and non-specific activity to suppress 
inflammatory symptoms of asthma. However, there are a portion of patients of asthma 
that remain symptomatic and inadequately controlled with conventional treatments, 
thus requiring additional individual theraputic options (Jayaram et al., 2006, Green, 
2002, Wenzel et al., 1999).  
2.1.1 Pathogenesis of asthma 
Previously, asthma is considered as T helper type 2 (Th2) disease of the 
airways through the increase production of IgE antibodies and prominent recruitment 
of mast cells and eosinophils to the airways (Lambrecht and Hammad, 2015). Recent 
evidences indicated that some inflammation in asthma is controlled by other subset of 
T cells including Th17 and Th9 cells (Lee et al., 2016a, Erpenbeck et al., 2003), 
indicating to heterogenosity of asthma. Although asthma can be induced by different 
factors leading to different phenotypes, its development mainly divided into 
sensitization and memory phase, and effector phase (Figure 2.1).  
Sensitization occurs upon the first encounter of foreign antigens such as 
microorganisms, allergens, and pollutants recognized by pattern recognition receptors 
(PRRs) expressed by airway epithelium. This recognization would leads to the 
production of pro-inflammatory cytokines [interleukin (IL)-33, thymic stromal 
lymphopoeitin (TLSP), tumor necrosis factor (TNF), IL-1β] that activates DCs, the 
antigen-presenting cells (APCs) responsible to modulate further immune responses 
(Hammad et al., 2009). These cytokines trigger DCs in several mechanisms, including 
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recruitment to the lung, migration and maturation to the lymph nodes and polarization 
and maintenance of Th2 cells (Lambrecht and Hammad, 2009). The prominent roles 
of Th2 cells in asthma are based on the increase level of IL-4 and IL-5 in asthmatic 
patients, correlating with the degree of eosinophilia in the airway and the abolishment 
of asthma features in Th2 cytokines-knockout animals (Robinson et al., 1992, Walker 
et al., 1994, Komai et al., 2003). IL-4 helps to mediate IgE synthesis by B cells, while 
IL-5 induces airway eosinophilia, where both are the prominent hallmarks of asthma 
(Steinke and Borish, 2001, Farne et al., 2017). These events would sensitize mast cells 
through binding of IgE with its high-affinity receptor complex (IgE-FcεRI), providing 
an initiation point for effector phase upon the next encounter with the same antigen 
(Reuter et al., 2010).  
In the effector phase, the same antigen encounter would immediately cross 
links with IgE-FcεRI complex on sensitized mast cells, releasing the mediators of 
inflammation such as histamine, leukotrines, cytokines, chemokines and proteases 
(Flint et al., 1985). The release of these mediators contributes to the airway 
constriction and remodelling, Goblet cell hyperplasia and influx of inflammatory cells 
including Th2 cells and eosinophils (Casale et al., 1987, Yamauchi et al., 2008, Yu 
and Chen, 2003). Continuous activation of mast cells and Th2 cells secrete cytokines 
(IL-4, IL-5, IL-9, IL-13) that further augment the airways tissue injury. While Th2 
cells are among the mediator for airway inflammation in the mild to moderate asthma, 
other T cell subsets starts to appear as the disease becomes more severe (Manni et al., 
2014). Th17 cells have been associated with severe asthma that is less responsive to 
corticosteroid by inducing neutrophils recruitment and increased inflammation of the 
airways (Wong et al., 2001, Newcomb and Peebles, 2013). Previously, sensitization 
phase is induced by the production of Th2 cells, mediated by IL-4, instead of Th1 
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cells by IL-12. In a more severe asthma, polarization of Th1 cells exacerbate the 
airway inflammations induced by Th2 cells (Rogala et al., 2015). Th9 cells are vital 
for recruitment and activation of mast cells during the early allergic responses while 
Th22 cells which are increased in children with asthma, involved in the recruitment of 
leukocytes and disrupt the integrity of epithelial lining in the lung (Jones et al., 2012, 





Figure 2.1 Pathogenesis of asthma. A First exposure to allergen and other antigenic 
stimuli induces epithelial cells to release mediators, which activates DCs to induce 
Th2-mediated responses including sensitization of mast cells. B Upon next encounter 
with the same antigen, sensitized mast cells released mediators that induce 
inflammatory effects potrayed by the manifestation of asthma. C Continuos activation 
of mast cells and Th2 cells augment the tissue injury and further initiate production of 




2.1.2 Treatment of asthma 
Clinically, treatment of asthma is approached based on severity and causing 
factors. In a common clinical setting, asthma is managed with two types of 
interventions including inhaled corticosteroids (ICS) and β2-agonist bronchodilators 
(Global Inititative for Asthma, 2019). Currently, there are combination drugs of ICS 
and bronchodilators such as Symbicort® and Seretide®, which have been effective in 
preventing asthma exacerbations (Bousquet et al., 2007). Although 90% of patients 
were effectively treated with these treatments, there are 5-10% of patients who do not 
respond well to these treatments that do not only cost more in healthcare, but also 
increased morbidity from the disease. Generally, treatment of asthma aims to achieve 
rapid improvement of the symptoms, as no disease-modifying treatment is available 
yet. Currently, new discovery on the pathophysiological mechanisms of asthma 
provides several strategies as potential disease-modifying treatment for asthma 
including allergen-specific immunotherapy (SIT), IgE as therapeutic target, inhibitors 
of mast cells as well as cytokine-based immunotherapies (Holgate and Polosa, 2008). 
SIT, for instance, is an immune modifying therapy that aims to induce long-term 
tolerance through the repeated exposure to allergens. The tolerance acquired through 
SIT is through the induction of Tregs and tolerogenic DCs that suppress the effector 
function of mast cells, eosinophils and T cells in asthma (Daniels et al., 2016). Apart 
from asthma, SIT in several types of allergy such as allergic rhinitis, atopic dermatitis 
and food allergy have been effective in inducing tolerance, thus reducing the 
symptoms and drugs intake in these diseases (Casale and Stokes, 2011). However SIT 
requires years of treatment for sufficient protection from disease, and several other 
challenges in terms of cost, extract availibity and age of patients, which limit the 
usage of this intervention in a bigger population (Chini et al., 2014).  
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2.1.3 Treatment with biologics such as TNF antagonist 
In inadequate controlled asthma, addition of biologics such as omalizumab, an 
IgE-targeted monoclonal antibodies, greatly reduces exacerbations in asthma and 
streroid use (Rodrigo et al., 2011).  Other biologics such as IL-5- and IL-13-specific 
drugs have also shown reduction of exacerbations in severe asthma in terms of reduce 
eosinophilia (Pavord et al., 2012, Gauvreau et al., 2011).  
In asthma pathogenesis, TNF is shown to play significant role and contributes 
to the early sensitization and late effector phase. TNF is secreted upon allergen or 
antigen challenge and continue to be responsible to the manifestations of asthma 
(Figure 2.1). Due to the significant role of TNF in the pathogenesis of asthma, the 
prospective of TNF antagonist as a disease-modifying treatment in asthma is 
anticipated. Currently, there are five TNF antagonists (three monoclonal antibodies; 
infliximab, adalimumab, and golimumab, a TNFR2 receptor etanercept and 
certolizumab, the PEGylated Fab antibodies) have been established as therapeutic 
options for inflammatory diseases in clinical settings.  
Etanercept, which comprises of TNFR2 and Fc portion of IgG1, have been 
shown to attenuate allergic lung inflammation in allergy model (Maillet et al., 2011).  
Etanercept is also shown to restore the expression and functions of FoxP3 on Tregs 
derived from allergic asthmatics (Lin et al., 2008). However, etanercept only showed 
to be well-tolerated therapy in moderate-to-severe asthma with no significant clinical 
efficacy in a randomized control trial (RCT) (Holgate et al., 2011). In another RCT, 
etanercept failed to attenuate airway inflammation in mild-to-moderate asthma 
eventhough it significantly increased the TNFR2 levels (Rouhani et al., 2005). 
Another anti-TNF monoclonal antibodies, golimumab, demonstrated to be unsuitable 
for treatment in severe asthma when it shows unfavorable risk-benefit profile in a 
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RCT (Wenzel et al., 2009).  Although the approach of TNF antagonism in asthma is 
conflicting, current discovery of anti-intuitive effects of TNF mediated by TNFR2 
revealed a novel strategy in the treatment of asthma.  
2.1.4 Requirement of tolerance to control asthma 
Asthma is associated with airway hyperresponsiveness and inflammations 
induced by allergens, excessive physical activities, smoke particulates and even 
obesity. Ideally, immune responses provide mechanism that induce and maintain 
tolerance towards excessive immune responses induced by these factors. One of them 
are CD4+FoxP3+ Tregs, the immunosupressive cells that normally dysregulated in 
disease conditions including asthma. Although observations in the number of Tregs 
were found to be conflicting, decreased, normal, or even increased in another study, 
the expression of FoxP3 protein, a critical marker for Tregs phenotype and function, 
was diminished (Provoost et al., 2009, Lin et al., 2008). Induction of Tregs from 
bacterial infection such as Helicobacter pylori (H. pylori) and Streptococcus 
pneumoniae (S. pneumoniae) efficiently protect animal against asthma (Arnold et al., 
2011, Thorburn et al., 2010). Enhancement of FoxP3 expression by mean of modified 
FoxP3 mRNA in allergen-induced animal rebalance the T cells population in the lung 
including Th2 and Th17 cells, thus attenuating the airway inflammations (Mays et al., 
2013, Zhang et al., 2014). Even more, increased Tregs number have been identified to 
be partially the underlying mechanism of protection against asthma in farm-exposed 
children (Lluis et al., 2014).  
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2.2 TNFR2+ regulatory T cells 
Tumor necrosis factor (TNF) is well-established as pro-inflammatory 
cytokine that contributes to pathological process in acute and chronic inflammation, 
autoimmune disease and cancer. In asthma, TNF is shown to be upregulated, 
particularly in severe asthma, and antagonism with TNF greatly improved the 
quality-of-life score of the patients (Berry et al., 2006). TNF is also shown to 
synergize with IL-17 to promote recruitment of neutrophil that underlies severe form 
of asthma (Manni et al., 2014). Furthermore, a meta analysis study suggested that 
TNF polymorphisms were significantly associated with asthma susceptibility (Huang 
et al., 2014). In asthma pathogenesis, TNF is secreted by epithelial barriers, mast 
cells and DCs, along with other pro-inflammmatory cytokines, to induce Th2 cells 
that lead to the immune cascades responsible for asthma symptoms (Figure 2.1). In 
models of airway inflammation, neutralization of TNF significantly decreased 
leukocytes recruitment such as eosinophils and neutrophils into the lung and airways 
(Lukacs et al., 1995, Maillet et al., 2011). Role of TNF in the pathogenesis of asthma 
is mainly regulated by TNFR1 signalling that bears death domain, thus inducing 
inflammation and apoptosis (Whitehead et al., 2017, Berry et al., 2006). In addition, 
TNF is involved in the downregulation of FoxP3 expression, thus abrogate the 
immune tolerance by Tregs in asthma (Lin et al., 2008).  
Meanwhile, one of the receptor of TNF, TNFR2, have been directly 
associated with the proliferation and maintenance of function in suppresive cells such 
as Tregs, tolerogenic DCs and myeloid suppressive cells (MDSCs) (Ahmad et al., 
2018). Thus, targeting this receptor in asthma and other allergic conditions to induce 
Tregs, suppressing the inflammatory cascade and maintaining homeostasis, is 
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anticipated (Figure 2.2). Recent studies identified TNFR2, which preferentially 
expressed on Tregs (CD25+ and Foxp3+ cells), constituted as a maximally 
suppressive Tregs than the TNFR2-negative population (Chen et al., 2008). Human 
CD25+TNFR2+ T cells are shown to have the highest level of regulatory markers of 
Tregs (CD54RO, CTLA-4, CCR-4, Foxp3), hyporesponsive to TCR stimulation and 
effectively inhibit the proliferation of Teffs compared to CD25+TNFR2- and CD25-
TNFR2+ cells (Chen et al., 2010b).  
Previously, it is established that TNFR2 is responsible to maintain the 
balance of TNF through regulation by DCs thus prevents inflammation (Martin et al., 
2014). Recently, studies indicate to the role of TNFR2 in promoting the 
differentiation and function of induced Tregs through the maintenance of Foxp3 
expression, both in vitro and in vivo (Yang et al., 2019, Tseng et al., 2019). TNFR2, 
which is preferentially expressed on human and mouse Tregs, are shown to involve 
in the inhibition of inflammatory responses by TNF through its regulation on Tregs 
(van Mierlo et al., 2008, Nguyen and Ehrenstein, 2016). In asthma model, impaired 
TNF-TNFR2 signalling promotes polarization of Th2 and Th17 cells, while inhibit 
Th1 and CD4+CD25+ T cells, thus exacerbate the airway inflammation (Li et al., 
2017). This group later confirmed that activation of TNF-TNFR2 signalling reduced 
the infiltration of eosinophils and neutrophils as well as the expression of Th2 and 
Th17 cytokines, alleviating inflammation in allergen-induced asthma model (Peng et 
al., 2019). However, there were studies which indicate otherwise. TNF that is 
promoted by natural killer (NK) cells induce Th2 response in virus-associated asthma 
model and the induction is via TNFR2 signalling instead of TNFR1 (Choi et al., 
2014). Meanwhile, in an obese asthma model, TNFR2 is required in the development 
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of airway hyperresponsiveness (AHR) and is associated with IL-17A, one of the 
phenotype in severe asthma (Williams et al., 2013).   
 
Figure 2.2 Potential of targeting Tregs through TNFR2. Induction of Tregs suppress 
inflammatory cascade in asthma pathogenesis including induction of tolerogenic DCs 
such as CD103+ DCs (Ahmad et al., 2018). 
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2.3 CD103+ dendritic cells 
It is known that Th2 cells plays a key feature to asthma pathogenesis. 
However, polarization of this cell population is induced by DCs that demonstrated the 
absence of DCs in animal transferred with Th2 cells failed to establish characteristics 
features of asthma (van Rijt et al., 2005). In asthma, DCs, which exist between the 
airway epithelium and underlying mucosa, would recognize and uptake the antigen to 
present it to T cells for further immune response (Hespel and Moser, 2012). The 
prominent role of DCs in asthma is further established by the suppression of Th2 
responses and even reverse the airway inflammations through the therapeutic transfer 
of DCs with immunoregulatory properties in experimental asthma. In another study, 
constant administration of ovalbumin-induced DCs have been shown to promote the 
development of Th17 and Th2 cells-associated airway inflammation (Raymond et al., 
2011). 
In human airways, especially lungs, DCs can be divided into several subsets, 
depending on the states of the airways, steady or inflamed (Lambrecht and Hammad, 
2009). In human, DCs are classified into three major subsets; plasmacytoid DC 
(pDCs), and two types of conventional DC (cDC1 and cDC2). In non-lymphoid 
tissues, cDCs consist of two major subsets: CD103+ DCs and CD11b+ DCs where 
CD11b+ DCs dominate the human blood. Meanwhile, CD103+CD11b+ DCs are 
among CD11b+ DCs counterpart that is unique to the intestine (Bain et al., 2017). 
Although all three subsets come from the same myeloid lineage, it is evidence that 
each subset bears distinct development and functional specialization (Table 2.1).  
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Table 2.1 Functional properties of DCs subsets. This table is adapted from Merad et al., (2013) unless cited otherwise 
Functional 
specialization 
CD103+ DCs CD11b+ DCs CD103+CD11b+ DCs 
Sensing 
 
• Langerin, CD24, Btla, c-kit, CD26, 
Xcr1, CD36, Clec9A, CD205 
• Express double-stranded viral RNA 
sensor, TLR3, TLR11 
• CD24, Btla, c-kit, CD209 
• Express high cytoplasmic viral sensor 
levels 
• Potent cytokine producers in steady state 
and upon stimulation 
• CX3CR1, F4/80, CD172a, CD64 
• Similar PRR expression profile to 
CD103+ DCs  
Activation of 
CD8+ T cells 
 
• Superior ability to present microbial 
antigens and cell-associated antigen 
to CD8+ T cells  
• Main source of IL-12 and IL-15 
• Able to cross present to CD8+ T cells 
NA 
Activation of 
CD4+ T cells 
• Induce CD4+ Th1 response  • Predominant role in MHC-II presentation 
in steady state 
• Prime Th2 cells  
• Induce Th2, Th17 and B cells in 
mucosa 
Tolerance 
• Negative selection of developing 
thymocytes and induction of Treg in 
thymus 
• In periphery, participate in 
deletional tolerance of self-reactive 
T cells and induce antigen-specific 
Tregs 
• Induce clonal deletion of autoreactive T 
cell or Tregs differentiation 
• Express ALDH to induce antigen-
specific Tregs 
• Able to induce peripheral antigen-








CD103+ DCs, the population of interest in the current study, are the largest 
population of DCs in the lung. This population of DCs resides in lung mucosa and 
vascular walls, mediating cell adhesion, migration and signalling that play a role in 
the homing of T cells in the lung (Sung et al., 2006).  Upon allergen challenge, this 
DCs subset is upregulated and prime Th2 cells, responsible for allergic airway 
inflammation (Sung et al., 2006, Nakano et al., 2012). Depletion of CD103+ DCs in 
the lung using allergen-specific cytotoxic T lymphocytes (CTLs) reduces allergic 
airway inflammation (Daniels et al., 2016). Significant role of CD103+ DCs in 
asthma is further confirmed by reduced airway hyperresponsiveness and eosinophil 
recruitment in CD103 knockout mice after aerosol challenge (Fear et al., 2016). 
Their study also observed a diminished number of Teff and Tregs as well as DCs in 
the same knockout model, indicating to the role of CD103 in the recruitment of these 
cells during airway inflammation (Fear et al., 2016). However, some studies reported 
different findings indicating to the protective role of CD103+ DCs against asthma. In 
asthmatic condition, CD103 knockout mice augmented lung inflammation when 
challenge to several antigens (Bernatchez et al., 2015, Blanchet et al., 2010, Conejero 
et al., 2017). This DCs subset induces protection by the production of IL-12, thus 
restraining Th2 and Th17 inflammatory responses. Furthermore, this DCs population 
and its expression on important subsets of T cells such as Tregs is shown to be 
increased upon antigen exposure (Bernatchez et al., 2015). CD103+ DCs promote 
tolerance in the airway by upregulate the expression of retinaldehyde dehydrogenase, 
among the co-factor for FoxP3 induction (Khare et al., 2013).  Furthermore, CD103+ 
DCs isolated from MLN have been shown to promote conversion of naïve T cells 
into FoxP3 T cells (Coombes et al., 2007). Similar to Tregs, CD103+ DCs is enriched 
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in the lungs of mice tolerized with H. pylori immunomodulators, providing 
protection against asthma (Engler et al., 2014).  
 
2.4 Targeting CD103+ DCs and TNFR2+ Tregs with gold nanoparticles 
As these subsets of cell population are well established to play significant 
protective role against asthma, targeting these immune cells is one of the most 
efficient strategies in the application of immunotherapies for asthma. This strategy is 
explored to deal with several challenges of conventional treatments of asthma such 
as corticosteroid-sensitive severe asthma, heterogenosity of asthma and other co-
morbid factors.  
2.4.1 Characteristics of gold nanoparticles 
The respiratory tract serves as an important portal of entry to our system that it 
raised both adverse effect concerns and opportunities for novel immunotherapy 
applications. Nanoparticles such as AuNPs have been proposed as a highly potential 
tool in immunotherapies due to its advantageous properties including customizable 
size and shapes, diverse surface functionality and biocompatibility.  
Studies have shown that smaller size and rod-shaped NPs were more readily 
internalized and efficiently take up by APCs such as DCs compared to bigger size 
and other-shaped NPs (Fernandez et al., 2015, Niikura et al., 2013, Oh et al., 2011). 
Since size and shape of NPs are of functional significance in immunotherapies, 
advances in the synthesis of AuNPs yielded customizable parameters that provide 
targeting capacity of AuNPs. In addition, AuNPs possessed high surface energy as 
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well as affinity towards numerous molecules including antibodies, antigenic 
peptides, nucleic acids, polymers and radioisotopes (Oh et al., 2011, Lee et al., 
2016b, Paul et al., 2014, Safari et al., 2012), enabled their functionality to be fine-
tuned for targeting capacities. Studies have shown that AuNPs is generally 
biocompatible and low in cytotoxicty compared to other inorganic NPs (Singh et al., 
2010, le Guével et al., 2015).  
Applications of AuNPs in the immunotherapies are based on its unique 
physiochemical properties including localized surface plasmon resonance (LSPR) 
and colloidal stability. LSPR generated by AuNPs is sensitive to its physiochemical 
characteristics, thus modification to these characteristics suggest to numerous 
potential applications, particularly in biomedical imaging (Abadeer and Murphy, 
2016, Gao et al., 2014). For colloidal stability that is crucial to avoid aggregation in 
biological medium, AuNPs can be surface functionalized with a number of 
compounds such as citrates, amines and thiols, hence effectively stabilize AuNPs for 
biological applications (Gao et al., 2012, Oh et al., 2013).  
2.4.2 Gold nanoparticles in asthma 
These manipulative properties of AuNPs have been of interest for targeted 
delivery of therapeutic agents through its interaction with APCs such as DCs that 
subsequently modulate further T cells immune responses (Ahmad et al., 2017). 
AuNPs preferentially accumulate in the lungs and effectively induced immune 
responses as indicated by increased cells such as macrophages, lymphocytes and 
monocytes upon exposure to AuNPs (Semmler-Behnke et al., 2008, Lipka et al., 
2010, Sung et al., 2011). In apolipoprotein E KO mice, a sensitive model for 
pulmonary effects, AuNPs is shown to be the least inflammatory and DNA damaging 
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compared to other carbonaceous particles (Jacobsen et al., 2009). Whereas, in LPS-
induced acute pulmonary inflammation model, AuNPs exhibited anti-inflammatory 
and antioxidative where peptide-conjugated AuNPs reduced the infiltration of 
inflammatory cells and increased of IL-10 (dos Santos Haupenthal et al., 2020, Wang 
et al., 2020).  
Despite the numerous applications of AuNPs such as photodynamic agent in 
cancer, anti-microbial agents and as a catalyst, its interaction with the immune 
system particularly in asthma and allergic condition is indisputably lacking. Like 
other ambient particulate pollutant (Penttinen et al., 2001, Frampton et al., 2004), 
environmental exposure to NPs including AuNPs has been associated with 
pulmonary inflammation and exacerbates the symptoms in existing asthma (Hussain 
et al., 2011, Klot et al., 2002). However, some studies also indicated to the protective 
effects of AuNPs against key features of asthma. In asthmatic mice, intranasal 
application of AuNPs shows inhibition to both inflammatory infiltrates and airway 
hyperactivity (Omlor et al., 2017, Barreto et al., 2015). Current study aims to 
investigate the effects of AuNPs on two cell populations of interest, TNFR2 
expressing Tregs, which was identified as a superior Tregs, and CD103+ DCs, which 
is shown to promote Tregs.   
 
 
